Rontalizumab is a potential new drug to treat lupus. It reduces the effects of the excessive interferon-alpha that is so characteristic of lupus. The researchers hoped to learn about the safety and tolerability of rontalizumab in people with mild lupus disease activity.
People with lupus may experience chronic fatigue, the exact causes of which are yet to be fully understood. There are a number of different energy-producing metabolic processes that may be affected in people with lupus.
People with lupus are at increased risk of cardiovascular disease, especially when taking steroids. The use of anti-malarial drugs, such as hydroxychloroquine, significantly reduces this risk.
This study examined the long-term safety of belimumab over a 4-year period in people with lupus. The results highlight the long-term safety of belimumab over a 4-year period.
The researchers hoped to learn about possible differences in treatment preferences for lupus among members of different racial/ethnic patient groups, as well as demographic or clinical characteristics associated with such preferences.
To update the ACR guidelines for the management of lupus nephritis, a team of lupus experts from around the country collaborated with the ACR. The researchers utilized extensive literature searches and expert opinions to develop the updated guidelines.
The findings highlight specific kinds of changes in lupus biomarkers that are most associated with effective use of belimumab in the treatment of lupus.
The results of this study reveal differences in autoantibody profiles over time in people with lupus, with important ethnicity-related differences, and their relationship to lupus-mediated organ damage over time.